

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0237  
Inventors: Monia and Cowsert  
Serial No.: Not Yet Assigned  
Filing Date: Herewith  
Examiner: Not Yet Assigned  
Group Art Unit: Not Yet Assigned  
Title: Antisense Inhibition of MAP Kinase  
Kinase 6 Expression

"Express Mail" Label No. EV001201091US  
Date of Deposit January 9, 2002

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Assistant Commissioner for Patents, Box PCT,  
Washington, D.C. 20231.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
  - ( ) Certification in Accordance with §1.97(e) is set forth below; or
  - ( ) The fee of \$180.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- ( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- (xx) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)

10/030599  
531 Rec'd PCT/T 09 JAN 2002

are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/357,073, filed July 19, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: January 9, 2002

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 04

Form PTO-1449 Modified		Docket No. RTSP- 0237	Serial No. <b>10/030599</b> <del>Not Yet Assigned</del>
List of Patents and Publications Cited by Application (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Applicant Monia and Cowsert	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Badger et al., Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function, J. Pharmacol. Exp. Ther., 1996, 279:1453-1461	
	AB	Cohen et al., The Critical Role of p38 MAP Kinase in T Cell HIV-1 Replication, Molecular Medicine, 1997, 3:339-346	
	AC	Cuenda et al., Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38), Embo J., 1997, 16:295-305	
	AD	Enslen et al., Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6, J. Biol. Chem., 1998, 273:1741-1748	
	AE	Goebeler et al., The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells, Blood, 1999, 93:857-865	
	AF	Goedert et al., Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases, Embo J., 1997, 16:3563-3571	
	AG	Han et al., Characterization of the structure and function of a novel MAP kinase kinase (MKK6), J. Biol. Chem., 1996, 271:2886-2891	
EXAMINER		DATE CONSIDERED	

Sheet 02 of 04

Form PTO-1449 Modified		Docket No. RTSP-0237	Serial No. <b>10/030599</b> Not Yet Assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Monia and Cowsert	
		Filing Date Herewith	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AH	Jackson et al., Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models, J. Pharmacol. Exp. Ther., 1998, 284:687-692	
	AI	Mackay et al., An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia, J. Biol. Chem., 1999, 274:6272-6279	
	AJ	Nagata et al., Activation of p38 MAP Kinase and JNK but not ERK is Required for Erythropoietin-Induced Erythroid Differentiation, Blood, 1998, 92:1859-1869	
	AK	Paul et al., Stress-activated protein kinases: activation, regulation and function, Cell Signal., 1997, 9:403-410	
	AL	Raingeaud et al., MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway, Mol. Cell. Biol., 1996, 16:1247-1255	
	AM	Suzuki et al., Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha, Blood, 1999, 93:341-349	
	AN	Zechner et al., MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner, J. Biol. Chem., 1998, 273:8232-8239	
EXAMINER		DATE CONSIDERED	

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. <b>RTSP-0237</b>	Serial No. <b>10/030599</b> Not Yet Assigned
		Applicant <b>Monia and Cowser</b>	
		Filing Date <b>Herewith</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AO	James W., "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes", <i>Antiviral Chemistry &amp; Chemotl.</i> 1991 2(4):191-214	
	AP	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays", <i>Nature Biotechnology</i> 1997 15:537-541	
EXAMINER		DATE CONSIDERED	

Sheet 04 of 04

Form PTO-1449 Modified				Docket No. <b>RTSP-0237</b>		Serial No. <b>10/030599</b>	
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Applicant <b>Monia and Cowsert</b>			
				Filing Date <b>Herewith</b>		Group <b>Not Yet Assigned</b>	
U.S. PATENT DOCUMENTS							
Examiner's Initial		Document No.	Date	Name	Class	Subclass	
	AA	5,736,381	04/07/1998	Davis et al.	435	252.3	
	AB	5,801,154	9-1-98	Baracchini et al	514	44	
	AC	6,033,910	3-7-00	Monia et al.	435	375	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
Examiner's Initial		Document No.	Date	Country	Translation YES NO		
	AO	WO 96/36642	11/21/1996	PCT	X		
	AP	WO 98/54203	12/03/1998	PCT	X		
	AQ	WO 97/22704	06/26/1997	PCT	X		
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						
EXAMINER				DATE CONSIDERED			